Exploration of Genome-Wide Circulating MicroRNA in Hepatocellular Carcinoma: MiR-483-5p as a Potential Biomarker

Background: MicroRNAs (miRNA) are abundant in the circulation and play a central role in diverse biologic processes; they may be useful for early diagnosis of hepatocellular carcinoma. Methods: We conducted a two-phase, case–control study (20 pairs for the discovery set and 49 pairs for the validation set) to test the hypothesis that genome-wide dysregulation of circulating miRNAs differentiates hepatocellular carcinoma cases from controls. Taqman low-density arrays were used to examine genome-wide miRNA expression for the discovery set, and quantitative real-time PCR was used to validate candidate miRNAs for both discovery and validation sets. Results: Sixty-six miRNAs were found to be significantly overexpressed in plasma of hepatocellular carcinoma cases compared with controls after adjusting for false discovery rate (P < 0.05). A volcano plot indicated that seven miRNAs had greater than 2-fold case–control differences with P < 0.01. Four significant miRNAs (miR-150, miR-30c, miR-483-5p, and miR-520b) detectable in all samples with varied expression levels were further validated in a validation set. MiR-483-5p was statistically significantly overexpressed in hepatocellular carcinoma cases compared with controls (3.20 vs. 0.82, P < 0.0001). Hepatocellular carcinoma risk factors and clinic-pathological characteristics did not influence miR-483-5p expression. The combination of plasma miR-483-5p level and hepatitis C virus status can significantly differentiate hepatocellular carcinoma cases from controls with an area under the curve of 0.908 (P < 0.0001). The sensitivity and specificity were, respectively, 75.5% and 89.8%. Conclusions: These preliminary results suggest the importance of dysregulated circulating miR-483-5p as a potential hepatocellular carcinoma biomarker. Impact: Confirmation of aberrant expression of miR-483-5p in a large prospective hepatocellular carcinoma study will provide support for its application to hepatocellular carcinoma detection. Cancer Epidemiol Biomarkers Prev; 22(12); 2364–73. ©2013 AACR.

[1]  Qian Wang,et al.  Bead‐based microarray analysis of microRNA expression in hepatocellular carcinoma: miR‐338 is downregulated , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  C. Croce,et al.  MicroRNA involvement in hepatocellular carcinoma , 2008, Journal of cellular and molecular medicine.

[3]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[4]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[5]  Thomas D. Schmittgen,et al.  Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival , 2008, Clinical Cancer Research.

[6]  Angela M. Liu,et al.  Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study , 2012, BMJ Open.

[7]  Y. Nagakawa,et al.  Deregulation of miR‐92a expression is implicated in hepatocellular carcinoma development , 2010, Pathology international.

[8]  X. Chen,et al.  Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. , 2010, Cancer research.

[9]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[10]  Peng-jun Zhang,et al.  Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies , 2010, Clinical science.

[11]  Anushya Muruganujan,et al.  PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium , 2009, Nucleic Acids Res..

[12]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[13]  Nathalie Wong,et al.  MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. , 2008, Gastroenterology.

[14]  C. Croce,et al.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.

[15]  A. Krogh,et al.  Programmed Cell Death 4 (PDCD4) Is an Important Functional Target of the MicroRNA miR-21 in Breast Cancer Cells* , 2008, Journal of Biological Chemistry.

[16]  J. Mott.  MicroRNAs involved in tumor suppressor and oncogene pathways: Implications for hepatobiliary neoplasia , 2009, Hepatology.

[17]  J. Sandgren,et al.  MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. , 2010, Endocrine-related cancer.

[18]  George A Calin,et al.  MicroRNA profiling in cancer. , 2011, Clinical science.

[19]  C. Larsson,et al.  The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma , 2011, Endocrine-related cancer.

[20]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[21]  Mihaela Zavolan,et al.  Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. , 2008, The American journal of pathology.

[22]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[23]  M. Sherman,et al.  Screening for hepatocellular carcinoma , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[24]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[25]  Bo Wang,et al.  Role of microRNA‐155 at early stages of hepatocarcinogenesis induced by choline‐deficient and amino acid–defined diet in C57BL/6 mice , 2009, Hepatology.

[26]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[27]  W. Tan,et al.  Circulating MicroRNAs, miR‐21, miR‐122, and miR‐223, in patients with hepatocellular carcinoma or chronic hepatitis , 2011, Molecular Carcinogenesis.

[28]  Wanjun Yu,et al.  Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. , 2011, Biochemical and biophysical research communications.

[29]  M. Albitar,et al.  Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma , 2011, Journal of clinical gastroenterology.

[30]  H. Allgayer,et al.  MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.

[31]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.

[32]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[33]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[34]  T. Wurdinger,et al.  Blood platelets contain tumor-derived RNA biomarkers. , 2011, Blood.

[35]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[36]  Tushar Patel,et al.  Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. , 2006, Gastroenterology.

[37]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[38]  P. Jansen,et al.  Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. , 2012, Journal of hepatology.

[39]  A. Tamori,et al.  Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. , 1994, Hepatology.

[40]  T. Fojo,et al.  MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy , 2011, Cancer.

[41]  Yang Li,et al.  Role of the miR‐106b‐25 microRNA cluster in hepatocellular carcinoma , 2009, Cancer science.

[42]  K. Choy,et al.  MiR-222 Overexpression Confers Cell Migratory Advantages in Hepatocellular Carcinoma through Enhancing AKT Signaling , 2010, Clinical Cancer Research.

[43]  S. Lowe,et al.  miR-221 overexpression contributes to liver tumorigenesis , 2009, Proceedings of the National Academy of Sciences.

[44]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[45]  Jianfeng Jin,et al.  Coexpression of an intronic microRNA and its host gene reveals a potential role for miR-483-5p as an IGF2 partner , 2011, Molecular and Cellular Endocrinology.

[46]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[47]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[48]  P. Qi,et al.  Serum MicroRNAs as Biomarkers for Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection , 2011, PloS one.

[49]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[50]  C. Croce,et al.  Oncogenic role of miR-483-3p at the IGF2/483 locus. , 2010, Cancer research.

[51]  Dennis B. Troup,et al.  NCBI GEO: archive for high-throughput functional genomic data , 2008, Nucleic Acids Res..

[52]  Kenzo Kobayashi,et al.  Prospective study of α‐fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma , 1994 .

[53]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[54]  Yoshiki Murakami,et al.  MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[55]  Yingdong Zhao,et al.  Analysis of Gene Expression Data Using BRB-Array Tools , 2007, Cancer informatics.

[56]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[57]  Zheng Wang,et al.  Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  H. Otu,et al.  Serum Proteomics and Biomarkers in Hepatocellular Carcinoma and Chronic Liver Disease , 2008, Clinical Cancer Research.